Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections

Expert Opinion on Investigational Drugs

Volumn 17, Issue 3, 2008, Pages 387-400

  Hammerschlag, Margaret R ^a   Sharma, Roopali ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

Acute bacterial exacerbactions of chronic bronchitis; Cethromycini; Community acquired pneumonia; Ketolides; Macrolides; Telithromycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFIXIME; CETHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; KETOCONAZOLE; LEVOFLOXACIN; MOXIFLOXACIN; RANITIDINE; RIFAMPICIN; SUCRALFATE; TELITHROMYCIN; THEOPHYLLINE; ANTIINFECTIVE AGENT; KETOLIDE;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BACILLUS ANTHRACIS; CARDIOTOXICITY; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; FRANCISELLA TULARENSIS; GASTROINTESTINAL TOXICITY; HAEMOPHILUS INFLUENZAE; HUMAN; LEGIONELLA PNEUMOPHILA; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NAUSEA; NEISSERIA GONORRHOEAE; NONHUMAN; PHARMACODYNAMICS; POSTANTIBIOTIC EFFECT; RESPIRATORY TRACT INFECTION; REVIEW; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; SUSPENSION; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING; YERSINIA PESTIS; ANIMAL; CHEMICAL STRUCTURE; COMMUNICABLE DISEASE; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KETOLIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 40949128223     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.3.387     Document Type: Review

References (78)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-72
2. Klugman KP. Clinical impact of antibiotic resistance in respiratory tract infections. Int J Antimicrob Agents 2007;29(Suppl 1):S6-10
3. Zhanel GG, Hisanaga T, Nichol K, et al. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Expert Opin Emerging Drugs 2003;8:297-321
4. Schlünzen F, Harms JM, Franceschi F, et al. Structural basis for the antibiotic activity of ketolides and azalides. Structure 2003;11:329-38
5. Lonks JR, Goldman DA. Telithromycin: a kerolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005;40:1657-64
6. Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycia: three case reports and a review of the literature. Ann Intern Med 2006;144:415-20
7. Dore DD, Dibello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. Drug Saf 2007;30:697-703
8. Ross DB. The FDA and the case of ketek. New Engl J Med 2007;356:1601-4
9. Lawrence LE. ABT-773 Abbott Laboratories. Curr Opin Investig Drugs 2001;2:766-72
10. No Authors Listed. Cethromycin. A-195773, A-195773-0, A-1957730, Abbott-195773, ABT-773. Drugs R&D 2007;8:95-102
11. Maz H, Clark R, Brazzale A, et al. Novel crythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. J Med Chem 2001;44:4137-56
12. Hernandez L, Sadrzadeh N, Krill S, et al. Preclinical pharmacokinetic profile of ABT-773 in mouse, rat, monkey, and dog. 39th Interscience Conference on Antimicrobial Agents Chemotherapy, San Francisco, USA, 26-29 September 1999. Abstract 2148
13. Edelstein PH, Higa F, Edelstein MAC. In vitro activity of ABT 773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2001;45:26815-90
14. Xuan D, Ye M, Kim M, et al. Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. J Pharm Pharmacol 2002;54:71-5
15. Heine HS, Bassett J, Miller L, et al. Susceptibility and efficacy of cethromycin in animal model of anthrax. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 27-30 September 2006. Abstract B-583
16. Guan Z, Fukmoto S, Fan L, et al. Human disposition and metabolism of orally administered ABT-773. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 16-19 December 2001. Abstract 942
17. Pradhan RS, Gustavson LE, Londo DD, et al. Single oral dose pharmacokinetics and safety of ABT-773 in healthy subjects. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000. Abstract 2135
18. Pradhan RS, Gustavson LE, Londo DD, et al. The bioavailability of ABT-773 is unaffected by food. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000. Abstract 2138
19. Conte JE, Golden JA, Kipps J, Zurlinden E. Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin. Antimicrob Agents Chemother 2004;48:3508-15
20. Garcia I, Pascual A, Ballesta S, et al. Accumulation and activity of cethromycin ABT-773; within human polymorphonuclear leucocytes. J Antimicrob Chemother 2003;52:24-8
21. Labro MT, Abdelghaffar H, Babin-Chevaye C. Interaction of the new ketolide ABT-773 cethromycin; with human polymorphonuclear neutrophils and the phagocytic cell line PBL-985 in vitro. Antimicrob Agents Chemother 2004;48:1096-104
22. Bosnar M, Kelneri Ž, Muni V, et al. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 2005;49:2372-77.
23. Bukofzer S, Gustavson L, Eiznhamer DA, et al. Safety and pharmacokinetics of cethromycin following administration of single and multiple doses to subjects with mild and moderate hepatic insufficiency. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 17-20 September 2007. Abstract A-796
24. Bukofzer S, Gustavson L, Eiznhamer DA, et al. Safety and pharmacokinetics of cethromycin following administration of multiple doses to subjects with severe renal impairment. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 17-20 September 2007. Abstract A-797
25. Capobianco JO, Cao Z, Shortridge VD, et al. Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000;44:1562-7
26. Zhensheng C, Zhong P, Xiaoan R, et al. Ribosome affinity and the prolonged molecular postantibiotic effect of cethromycin (ABT-773) in Haemophilus influenzae. Int J Antimicrob Agents 2004;24:362-8
27. Bundtzen RW, Gerber AU, Cohn DL, et al. Postantibiotiic suppression of bacterial growth. Rev Infect Dis 1981;3:28-47
28. Davies TA, Ednie LM, Hoellman DM, et al. Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob Agents Chemother 2000;44:1894-9
29. Credito KL, Lin G, Pankuch GA, et al. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob Agents Chemother 2001;45:67-92
30. Neuhauser M, Prause J, Danziger L, et al. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 2001;45:3613-5
31. Kim MK, Zhou W, Tessier P, et al. Bactericidal effect and pharmacodynamics of cethromycin ABT-773; in a murine pneumococcal pneumonia model. Antimicrob Agents Chemother 2002;46:3185-92
32. Craig W, Andes D. In vivo pharmacodynamics of ABT-773, a new ketolide. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000. Abstract 2139
33. Nilius AM, Bui MH, Almer D, et al. Comparative in vitro activity of ABT-773, a novel antibiotic ketolide. Antimicrob Agents Chemother 2001;45:2163-8
34. Goldstein EJ, Conrads G, Citron DM, et al. In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob Agents Chemother 2001;45:2363-7
35. Hamilton-Miller JMT, Shah S. In vitro activity of ABT-773 cethromycin; against erythromycin-resistant Streptococcus pneumoniae: correlation with extended MLSK phenotypes. J Antimicrob Chemother 2002;50:907-13
36. Morosini MI, Canton R, Loza E, et al. Streprococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain; in vitro activities of telithromycin and cethromycin. J Antimicrob Chemother 2003;52:50-5
37. Mason EO, Lamberth LB, Wald ER, et al. In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillins or macrolides. Antimicrob Agents Chemother 2003;47:166-9
38. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian respiratory organism susceptibilicy study, 1997 to 2002. Antimicrob Agents Chemother 2003;47:1867-74
39. Bozzolasco M, Debbia EA, Roveta S, et al. In vitro activity of ABT-773, a new ketolide derivative exhibiting innovative microbiological properties against well-characterized antibiotic resistant pathogens in Italy. Int J Antimicrob Agents 2004;23:11-6
40. Jorgensen JH, Crawford SA, Mcelmeel ML, et al. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2004;48:605-7
41. Draghi DC, Pillar CM, Torres MK, et al. In vitro activity of cethromycin against a recent and diverse collection of Haemophilus influenzae isolates. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 17-20 September 2007. Abstract E-1631
42. Sahm DF, Draghi DC, Brown NP, et al. Baseline surveillance profile of cethromycin activity against Streptococcus pneumoniae; results of the US surveillance initiative. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 17-20 September 2007. Abstract E-1632
43. Eiznhamer DA, Sahm DF, Poppe SM, et al. In vitro activity of cethromycin, a novel antibiotic under clinical development, against S. pneumoniae not susceptible to telithromycin. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 17-20 September 2007. Abstract E-1633
44. Citron DM, Appleman MD. Comparative activities of ABT-773 against 362 clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother 2001;45:345-8
45. Strigl S, Roblin PM, Reznik T, Hammerschlag MR. In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae. Antimicrob Agents Chemother 2000;44:1112-3
46. Hammerschlag MR, Reznik T, Roblin PM, et al. Microbiologic efficacy of ABT-773 cethromycin; for treatment of community acquired pneumonia due to Chlamydia pneumoniae. J Antimicrob Chemother 2003;51:1025-8
47. Miyashita N, Fukano H, Yoshida Y, et al. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2003;52:497-9
48. Waites KB, Crabb DM, Duffy LB. In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas. Antimicrob Agents Chemother 2003;47:391-42
49. Jung R, Danziger LH, Pendland SL. Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila. J Antimicrob Chemother 2002;49:857-61
50. Davies TA, Dewasse BF, Jacobs MR, Appelbaum PC. In vitro development of resistance to telithromycin (HMR 3647), four macrolides. clindamycin. and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000;44:414-7
51. Nilius AM, Hensey-Rudloff DM, Reimann MA, Flamm RK. Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens. J Antimicrob Chemother 2002;49:831-6
52. Wolter N, Smith AM, Low DA, Klugman, KP. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 2007;51:1092-5
53. Mitten MJ, Meulbrock J, Nukkala M, et al. Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob Agents Chemother 2001;45:2585-93
54. Capitano B, Maglio D, Banevicius MA, et al. Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model. Int J Antimicrob Agents 2003;22:588-93
55. Azoulay-Dupuis E, Mohler J, Bedos JP, et al. Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model. Antimicrob Agents Chemother 2006;50:3033-8
56. Rios AM, Mejias A, Chavez-Bueno S, et al. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob Agents Chemother 2004;48:2897-904
57. Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr Infect Dis J 1995;14:471-7
58. Harris J-A, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children. Pediatr Infect Dis J 1998; 17:865-71
59. Hammerschlag MR, Roblin PM. Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother 2000;44:1409
60. Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 2000;15:149-52
61. Roblin PM, Montalban G, Hammerschlag MR. Susceptibility to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994;38:1588-9
62. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community acquired pneumonia. Antimicrob Agents Chemother 1998;42:194-6
63. Bukofzer S, Valdes J, Eiznhamer DA, et al. A phase 2 comparative study of the safety and efficacy of two oral doses of cethromycin for the treatment of community acquired pneumonia (CAP). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA, 27-30 September 2006. Abstract L-1442
64. Bukofzer S, Gu Y, Eiznhamer DA, et al. A phase 2/3 comparative study of the safety and efficacy of two oral doses of cethromycin for the treatment of community acquired pneumonia (CAP). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 27-30 September 2006. Abstract L-1445
65. Valdes J, Bukofzer S, Eiznhamer DA, et al. A phase 2 comparative study of the safety and efficacy of three oral doses of cethromycin for the treatment of acute bacterial exacerbations of chronic bronchitis ABECB). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 27-30 September 2006. Abstract L-1443
66. Bukofzer S, Gu Y, Eiznhamer DA, et al. A phase 3 study of cethromycin 150 mg QD and levofloxacin 500 mg QD for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA 27-30 September 2006. Abstract L-1444
67. Gustavson LE, Ye X, Beason J, et al. ABT-773 has no clinically-important effect on the pharmacokinetics and safety of theophylline. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 16-19, December 2001. Abstract A-941
68. Pletz MW, Preechachatchaval V, Bulitta J, et al. ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. Antimicrob Agents Chemother 2003;47:1129-31
69. Bukofzer S, Gustavson L, Eiznhamer DA, et al. Assessment of the pharmacokinetic interaction between cethromycin and ketoconazole. 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, USA, 4-7 October 2007. Abstract 444
70. Bukofzer S, O'Dea R. Gustavson L, et al. Assessment of the pharmacokinetic interaction between cethromycin and rifampin. 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, USA, 4-7 October 2007. Abstract 443
71. Parnharn MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin infect Dis 2005;18:125-31
72. Bukofzer S, Gustavson L, Xu Z, et al. Single dose bioavailability of cethromycin granules for suspension formulation in healthy adult subjects. 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, USA, 4-7 October 2007. Abstract 450
73. Centers for Disease Control and Prevention. Update to CDC's Sexually Transmitted Treatment Guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. Morbid Mortal Week Rep 2007;56.333-6
74. Hunfeld K-P, Wichelhaus Ta, R del R, et al. Comparison of in vitro ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemotber 2004;48:344-7
75. Heine HS, Miller I, Eiznhamer DA, et al. Antimicrobial activity of cethromycin, a novel ketolide, tested against diverse collections of Bacillus anthracis and Yersinia pestis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 27-30 September 2006. Abstract E-1853
76. Heine HS, Miller I, Bassett J, et al. Antimicrobial activity of cethromycin, a novel ketolide, tested against a diverse collection of Franciscella tularensis strains. 47th Interscience Conference-on Antimicrobial Agents and Chemotherapy, Chicago, USA, 17-20 September 2007. Abstract E-1634
77. Sivko G, Gebhardt K, Olson P, et al. Efficacy of cethromycin against a lethal inhalation anthrax challenge in rhesus macaques. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA 17-20 September 2007, Abstract B-2031
78. Cynamon MH, Carter Jl, Shoen CM. Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 2000;44:2895-6